(FDMT) 4D Molecular Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 484m USD | Total Return: 302.4% in 12m

Gene Therapy, Drug Development, Vector Platform
Total Rating 59
Safety 70
Buy Signal -0.04
Biotechnology
Industry Rotation: +6.6
Market Cap: 484M
Avg Turnover: 6.57M USD
ATR: 6.86%
Peers RS (IBD): 81.3
Risk 5d forecast
Volatility86.9%
Rel. Tail Risk-11.8%
Reward TTM
Sharpe Ratio1.82
Alpha231.05
Character TTM
Beta0.943
Beta Downside1.402
Drawdowns 3y
Max DD93.00%
CAGR/Max DD-0.14
EPS (Earnings per Share) EPS (Earnings per Share) of FDMT over the last years for every Quarter: "2021-03": -0.61, "2021-06": -0.28, "2021-09": -0.82, "2021-12": -0.85, "2022-03": -0.82, "2022-06": -0.87, "2022-09": -0.79, "2022-12": -0.84, "2023-03": -0.88, "2023-06": -0.77, "2023-09": -0.24, "2023-12": -0.75, "2024-03": -0.66, "2024-06": -0.63, "2024-09": -0.79, "2024-12": -0.9, "2025-03": -0.86, "2025-06": -0.98, "2025-09": -1.01, "2025-12": 0.43, "2026-03": 0,
EPS CAGR: 53.38%
EPS Trend: 41.6%
Last SUE: 2.38
Qual. Beats: 2
Revenue Revenue of FDMT over the last years for every Quarter: 2021-03: 2, 2021-06: 14.58, 2021-09: 1.366, 2021-12: 0.092, 2022-03: 1.219, 2022-06: 0.162, 2022-09: 0.5, 2022-12: 1.247, 2023-03: 0.298, 2023-06: 0.239, 2023-09: 20.204, 2023-12: -0.019, 2024-03: 0.028, 2024-06: 0.005, 2024-09: 0.003, 2024-12: 0.001, 2025-03: 0.014, 2025-06: 0.015, 2025-09: 0.09, 2025-12: 85.09, 2026-03: null,
Rev. CAGR: 210.24%
Rev. Trend: 15.1%
Last SUE: 4.00
Qual. Beats: 1

Warnings

Altman Z'' -14.06 < 1.0 - financial distress zone

Volatile

Tailwinds

Pead

Description: FDMT 4D Molecular Therapeutics

4D Molecular Therapeutics Inc. (FDMT) is a late-stage biotechnology company specializing in gene therapy development.

Their core business model involves using a proprietary platform, Therapeutic Vector Evolution, to develop adeno-associated virus (AAV) vectors. AAV gene therapies are a key area of focus in the biotechnology sector due to their potential for long-term therapeutic effects from a single administration.

Their lead candidate, 4D-150, targets retinal vascular diseases like wet age-related macular degeneration and diabetic macular edema. This involves sustained production of anti-VEGF proteins directly in the retina. The company also has a pipeline of other gene therapy candidates for conditions such as cystic fibrosis, geographic atrophy, alpha-1 anti-trypsin deficiency lung disease, and Fabry disease, all in various stages of development from preclinical to Phase 1 clinical trials.

FDMT engages in collaborations and licensing agreements with other biotechnology and pharmaceutical companies, a common strategy in the capital-intensive drug development industry to share risks and resources.

To further understand FDMTs market position and future prospects, consider exploring additional data and analytics on ValueRay.

Headlines to Watch Out For
  • 4D-150 clinical trial results impact future revenue potential
  • Pipeline development costs strain company financials
  • Regulatory approval for gene therapies poses significant risk
  • Collaboration agreements provide non-dilutive funding
Piotroski VR‑10 (Strict) 0.0
Net Income: -140.1m TTM > 0 and > 6% of Revenue
FCF/TA: -0.19 > 0.02 and ΔFCF/TA 5.23 > 1.0
NWC/Revenue: 433.2% < 20% (prev 1.10m%; Δ -1.10m% < -1%)
CFO/TA -0.19 > 3% & CFO -109.1m > Net Income -140.1m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 9.39 > 1.5 & < 3
Outstanding Shares: last quarter (57.9m) vs 12m ago 7.39% < -2%
Gross Margin: -14.04% > 18% (prev -1.71k%; Δ 169k% > 0.5%)
Asset Turnover: 15.12% > 50% (prev 0.01%; Δ 15.11% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -14.06
A: 0.65 (Total Current Assets 413.1m - Total Current Liabilities 44.0m) / Total Assets 566.7m
B: -1.26 (Retained Earnings -716.3m / Total Assets 566.7m)
C: -0.28 (EBIT TTM -159.5m / Avg Total Assets 563.5m)
D: -11.72 (Book Value of Equity -715.6m / Total Liabilities 61.0m)
Altman-Z'' Score: -14.06 = D
What is the price of FDMT shares? As of April 09, 2026, the stock is trading at USD 10.10 with a total of 629,422 shares traded.
Over the past week, the price has changed by +2.33%, over one month by +15.69%, over three months by +38.36% and over the past year by +302.39%.
Is FDMT a buy, sell or hold? 4D Molecular Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy FDMT.
  • StrongBuy: 5
  • Buy: 4
  • Hold: 2
  • Sell: 0
  • StrongSell: 1
What are the forecasts/targets for the FDMT price?
Analysts Target Price 31.1 208%
4D Molecular Therapeutics (FDMT) - Fundamental Data Overview as of 07 April 2026
P/S = 5.6798
P/B = 0.9571
Revenue TTM = 85.2m USD
EBIT TTM = -159.5m USD
EBITDA TTM = -159.5m USD
Long Term Debt = 21.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.59m USD (from shortTermDebt, last quarter)
Debt = 21.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -381.2m USD (recalculated: Debt 21.4m - CCE 402.7m)
Enterprise Value = 102.7m USD (484.0m + Debt 21.4m - CCE 402.7m)
 Interest Coverage Ratio = unknown (Ebit TTM -159.5m / Interest Expense TTM 0.0)
 EV/FCF = -0.93x (Enterprise Value 102.7m / FCF TTM -110.3m)
 FCF Yield = -107.4% (FCF TTM -110.3m / Enterprise Value 102.7m)
 FCF Margin = -129.5% (FCF TTM -110.3m / Revenue TTM 85.2m)
 Net Margin = -164.4% (Net Income TTM -140.1m / Revenue TTM 85.2m)
Gross Margin = -14.04% ((Revenue TTM 85.2m - Cost of Revenue TTM 97.2m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.18 (Enterprise Value 102.7m / Total Assets 566.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 21.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -126.0m (EBIT -159.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.39 (Total Current Assets 413.1m / Total Current Liabilities 44.0m)
Debt / Equity = 0.04 (Debt 21.4m / totalStockholderEquity, last quarter 505.7m)
 Debt / EBITDA = 2.39 (negative EBITDA) (Net Debt -381.2m / EBITDA -159.5m)
 Debt / FCF = 3.46 (negative FCF - burning cash) (Net Debt -381.2m / FCF TTM -110.3m)
 Total Stockholder Equity = 441.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.86% (Net Income -140.1m / Total Assets 566.7m)
RoE = -31.75% (Net Income TTM -140.1m / Total Stockholder Equity 441.3m)
RoCE = -34.48% (EBIT -159.5m / Capital Employed (Equity 441.3m + L.T.Debt 21.4m))
 RoIC = -28.56% (negative operating profit) (NOPAT -126.0m / Invested Capital 441.3m)
 WACC = 8.91% (E(484.0m)/V(505.4m) * Re(9.30%) + D(21.4m)/V(505.4m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.30% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 21.67%
 [DCF] Fair Price = unknown (Cash Flow -110.3m)
 EPS Correlation: 41.62 | EPS CAGR: 53.38% | SUE: 2.38 | # QB: 2
Revenue Correlation: 15.05 | Revenue CAGR: 210.2% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-06-30): EPS=-0.98 | Chg7d=+0.006 | Chg30d=-0.111 | Revisions Net=-2 | Analysts=9
EPS current Year (2026-12-31): EPS=-3.83 | Chg7d=-0.078 | Chg30d=-0.347 | Revisions Net=-7 | Growth EPS=-58.1% | Growth Revenue=-88.4%
EPS next Year (2027-12-31): EPS=-3.85 | Chg7d=-0.101 | Chg30d=-0.272 | Revisions Net=-5 | Growth EPS=-0.8% | Growth Revenue=+53.1%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle